<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35570987</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2468-0249</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Kidney international reports</Title>
          <ISOAbbreviation>Kidney Int Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Anticancer Drug-Induced Capillary Leak Syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>945</StartPage>
          <EndPage>953</EndPage>
          <MedlinePgn>945-953</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ekir.2022.02.014</ELocationID>
        <Abstract>
          <AbstractText>The term capillary leak syndrome (CLS) describes the manifestations associated with an increased capillary permeability to proteins leading to an escape of plasma from the blood circulatory system to surrounding tissues, muscle, organs, or body cavities. This results clinically in the typical triad of hypotension, edema, and elevated hematocrit. The more severe cases of CLS may present with cardiovascular collapse, shock, and death. The most classic form of this pathology is represented by the idiopathic systemic CLS (SCLS) also called Clarkson's disease, but capillary leaks are also described as adverse drug reactions foremost among which are anticancer drugs. This review will focus on oncologic drugs such as gemcitabine, therapeutic growth factors or cytokines, and monoclonal antibodies (mAbs) that appear now as the strongest candidates for anticancer drug-induced CLS.</AbstractText>
          <CopyrightInformation>© 2022 International Society of Nephrology. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Izzedine</LastName>
            <ForeName>Hassan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathian</LastName>
            <ForeName>Alexis</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS, Institut E3M, Service de Médecine Interne 2, le Syndrome des Anti-phospholipides et autres maladies auto-immunes rares, Centre de Référence pour le Lupus, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amoura</LastName>
            <ForeName>Zahir</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS, Institut E3M, Service de Médecine Interne 2, le Syndrome des Anti-phospholipides et autres maladies auto-immunes rares, Centre de Référence pour le Lupus, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ng</LastName>
            <ForeName>Jia H</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jhaveri</LastName>
            <ForeName>Kenar D</ForeName>
            <Initials>KD</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Kidney Int Rep</MedlineTA>
        <NlmUniqueID>101684752</NlmUniqueID>
        <ISSNLinking>2468-0249</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anticancer drugs</Keyword>
        <Keyword MajorTopicYN="N">capillary leak syndrome</Keyword>
        <Keyword MajorTopicYN="N">cytokines</Keyword>
        <Keyword MajorTopicYN="N">gemcitabine</Keyword>
        <Keyword MajorTopicYN="N">immunotherapy</Keyword>
        <Keyword MajorTopicYN="N">monoclonal antibodies</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>3</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35570987</ArticleId>
        <ArticleId IdType="pmc">PMC9091576</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ekir.2022.02.014</ArticleId>
        <ArticleId IdType="pii">S2468-0249(22)01194-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kapoor P., Greipp P.T., Schaefer E.W., et al.  Idiopathic systemic capillary leak syndrome (Clarkson’s disease): the Mayo clinic experience. Mayo Clin Proc. 2010;85:905–912. doi: 10.4065/mcp.2010.0159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/mcp.2010.0159</ArticleId>
            <ArticleId IdType="pmc">PMC2947962</ArticleId>
            <ArticleId IdType="pubmed">20634497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aulagnon F., Lapidus N., Canet E., et al.  Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis. 2015;65:851–859. doi: 10.1053/j.ajkd.2014.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2014.10.012</ArticleId>
            <ArticleId IdType="pubmed">25480521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carreras E., Fernández-Avilés F., Silva L., et al.  Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010;45:1417–1422. doi: 10.1038/bmt.2009.363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2009.363</ArticleId>
            <ArticleId IdType="pubmed">20062097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin J.I., Lee K.H., Lee I.R., et al.  Systemic capillary leak syndrome (Clarkson syndrome) in cancer patients: a systematic review. J Clin Med. 2018;7:418. doi: 10.3390/jcm7110418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm7110418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suntharalingam G., Perry M.R., Ward S., et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028. doi: 10.1056/NEJMoa063842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa063842</ArticleId>
            <ArticleId IdType="pubmed">16908486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolberg-Stolik O.C., Putterman C., Rubinow A., et al.  Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest. 1993;104:123–126. doi: 10.1378/chest.104.1.123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.104.1.123</ArticleId>
            <ArticleId IdType="pubmed">8325053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Z., Ghosh C.C., Patel R., et al.  Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome) Blood. 2012;119:4321–4332. doi: 10.1182/blood-2011-08-375816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-08-375816</ArticleId>
            <ArticleId IdType="pmc">PMC3359743</ArticleId>
            <ArticleId IdType="pubmed">22411873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Druey K.M., Greipp P.R. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010;153:90–98. doi: 10.7326/0003-4819-153-2-201007200-00005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-153-2-201007200-00005</ArticleId>
            <ArticleId IdType="pmc">PMC3017349</ArticleId>
            <ArticleId IdType="pubmed">20643990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pineton de Chambrun M., Gousseff M., Mauhin W., et al. EurêClark Study Group  Intravenous immunoglobulins improve survival in monoclonal gammopathy-associated systemic capillary-leak syndrome. Am J Med. 2017;130:1219.e19–1219.e27. doi: 10.1016/j.amjmed.2017.05.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2017.05.023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siddall E., Khatri M., Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92:37–46. doi: 10.1016/j.kint.2016.11.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2016.11.029</ArticleId>
            <ArticleId IdType="pubmed">28318633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eo T.S., Chun K.J., Hong S.J., et al.  Clinical presentation, management, and prognostic factors of idiopathic systemic capillary leak syndrome: a systematic review. J Allergy Clin Immunol Pract. 2018;6:609–618. doi: 10.1016/j.jaip.2017.07.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2017.07.021</ArticleId>
            <ArticleId IdType="pubmed">28939140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Druey K.M., Parikh S.M. Idiopathic systemic capillary leak syndrome (Clarkson disease) J Allergy Clin Immunoll. 2017;140:663–670. doi: 10.1016/j.jaci.2016.10.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2016.10.042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guffroy A., Dervieux B., Gravier S., et al.  Systemic capillary leak syndrome and autoimmune diseases: a case series. Semin Arthritis Rheum. 2017;46:509–512. doi: 10.1016/j.semarthrit.2016.08.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2016.08.001</ArticleId>
            <ArticleId IdType="pubmed">27637319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mertz P., Lebrun-Vignes B., Salem J.E., Arnaud L. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. J Allergy Clin Immunol. 2019;143:433–436. doi: 10.1016/j.jaci.2018.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.09.001</ArticleId>
            <ArticleId IdType="pubmed">30244023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeong G.H., Lee K.H., Lee I.R., et al.  Incidence of capillary leak syndrome as an adverse effect of drugs in cancer patients: a systematic review and meta-analysis. J Clin Med. 2019;8 doi: 10.3390/jcm8020143. pii: E143. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm8020143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu W., Xia Q., Luo R.J., et al.  In vitro study of the antagonistic effect of low-dose liquiritigenin on gemcitabine-induced capillary leak syndrome in pancreatic adenocarcinoma via inhibiting ROS-mediated signalling pathways. Asian Pac J Cancer Prev. 2015;16:4369–4376. doi: 10.7314/apjcp.2015.16.10.4369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/apjcp.2015.16.10.4369</ArticleId>
            <ArticleId IdType="pubmed">26028101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardini A.C., Aquilina M., Oboldi D., et al.  Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013;13:542. doi: 10.1186/1471-2407-13-542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-13-542</ArticleId>
            <ArticleId IdType="pmc">PMC3840643</ArticleId>
            <ArticleId IdType="pubmed">24215543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baron D., Mayo A., Kluger Y. Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease. Clin Oncol (R Coll Radiol) 2006;18:90–91. doi: 10.1016/j.clon.2005.09.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clon.2005.09.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas S., Nik S., Corrie P.G. Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol) 2004;16:577–579. doi: 10.1016/j.clon.2004.06.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clon.2004.06.019</ArticleId>
            <ArticleId IdType="pubmed">15630853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pulkkanen K., Kataja V., Johansson R. Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report. J Chemother. 2003;15:287–289. doi: 10.1179/joc.2003.15.3.287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1179/joc.2003.15.3.287</ArticleId>
            <ArticleId IdType="pubmed">12868557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajwa R., Starr J., Daily K. Gemcitabine-induced chronic systemic capillary leak syndrome. BMJ Case Rep. 2017;2017 doi: 10.1136/bcr-2017-221068. bcr2017221068. </Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2017-221068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Pas T., Curigliano G., Franceschelli L., et al.  Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol. 2001;12:1651–1652. doi: 10.1023/a:1013163831194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/a:1013163831194</ArticleId>
            <ArticleId IdType="pubmed">11822767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler U., Jensen M., Manzke O., et al.  Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood. 1999;94:2217–2224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10498591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg S.A., Lotze M.T., Muul L.M., et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–1492. doi: 10.1056/NEJM198512053132327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198512053132327</ArticleId>
            <ArticleId IdType="pubmed">3903508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spitzer T.R. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469–475. doi: 10.1038/bmt.2014.296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2014.296</ArticleId>
            <ArticleId IdType="pubmed">25581406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luesink M., Jansen J.H. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol. 2010;151:209–220. doi: 10.1111/j.1365-2141.2010.08325.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2010.08325.x</ArticleId>
            <ArticleId IdType="pubmed">20735400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantarjian H., Gandhi V., Cortes J., et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003;102:2379–2386. doi: 10.1182/blood-2003-03-0925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2003-03-0925</ArticleId>
            <ArticleId IdType="pubmed">12791647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabhan C., Davis N., Bitran J.D., et al.  Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011;117:1490–1497. doi: 10.1002/cncr.25603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.25603</ArticleId>
            <ArticleId IdType="pubmed">21425150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faderl S., Ravandi F., Huang X., et al.  A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008;112:1638–1645. doi: 10.1182/blood-2007-11-124602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-11-124602</ArticleId>
            <ArticleId IdType="pmc">PMC4081352</ArticleId>
            <ArticleId IdType="pubmed">18565853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kesik V., Atas E., Korkmazer N., Babacan O. Clofarabine associated capillary leak syndrome in a child with lymphoma successfully treated with intravenous immunoglobulin. J Cancer Res Ther. 2015;11:653. doi: 10.4103/0973-1482.138028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0973-1482.138028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baytan B., Ozdemir O., Gunes A.M., Dönmez O. Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:144–146. doi: 10.1097/MPH.0b013e3181bf298b.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MPH.0b013e3181bf298b</ArticleId>
            <ArticleId IdType="pubmed">20057324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CLOLAR  . Genzyme Corporation; 2013. Prescribing information. Warnings and Precautions; pp. 1–5.</Citation>
        </Reference>
        <Reference>
          <Citation>Abboud C.N., Lang N., Fung H., et al.  Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Support Care Cancer. 2019;27:2569–2577. doi: 10.1007/s00520-018-4522-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00520-018-4522-5</ArticleId>
            <ArticleId IdType="pubmed">30443809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez-Sandoval J.C., Varela-Jimenez R., Morales-Buenrostro L.E. Capillary leak syndrome as a complication of antibody-mediated rejection treatment: a case report. CEN Case Rep. 2018;7:110–113. doi: 10.1007/s13730-018-0306-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13730-018-0306-5</ArticleId>
            <ArticleId IdType="pmc">PMC5886937</ArticleId>
            <ArticleId IdType="pubmed">29344912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsiao S.C., Wang M.C., Chang H., Pei S.N. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma. Ann Pharmacother. 2010;44:587–589. doi: 10.1345/aph.1M585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1345/aph.1M585</ArticleId>
            <ArticleId IdType="pubmed">20150504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee D.W., Gardner R., Porter D.L., et al.  Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126:1048] Blood. 2014;124:188–195. doi: 10.1182/blood-2014-05-552729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-05-552729</ArticleId>
            <ArticleId IdType="pmc">PMC4093680</ArticleId>
            <ArticleId IdType="pubmed">24876563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing M.G., Moreau T., Greenwood J., et al.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996;98:2819–2826. doi: 10.1172/JCI119110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI119110</ArticleId>
            <ArticleId IdType="pmc">PMC507749</ArticleId>
            <ArticleId IdType="pubmed">8981930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ploessl C., Pan A., Maples K.T., Lowe D.K. Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann Pharmacother. 2016;50:416–422. doi: 10.1177/1060028016632013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028016632013</ArticleId>
            <ArticleId IdType="pubmed">26917818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F., Yang J., Li Z. Trastuzumab-induced systemic capillary leak syndrome in a breast cancer patient. Pathol Oncol Res. 2014;20:435–437. doi: 10.1007/s12253-013-9713-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-013-9713-2</ArticleId>
            <ArticleId IdType="pubmed">24163290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witzel I.D., Müller V., Harps E., et al.  Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol. 2008;19:191–192. doi: 10.1093/annonc/mdm542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdm542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lescure C., Lescoat A., Salé A., et al.  Systemic capillary leak syndrome (Clarkson’s disease) as a complication of anti-programmed death 1 immunotherapy. J Thorac Oncol. 2019;14:e131–e132. doi: 10.1016/j.jtho.2019.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtho.2019.02.003</ArticleId>
            <ArticleId IdType="pubmed">31122567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polishchuk I., Yakobson A., Zemel M., et al.  Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy. Immunotherapy. 2021;13:807–811. doi: 10.2217/imt-2020-0335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/imt-2020-0335</ArticleId>
            <ArticleId IdType="pubmed">33969699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin H., Vlaminck B., Owoyemi I., et al.  Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction. Mayo Clin Proc Innov Qual Outcomes. 2021;5:670–674. doi: 10.1016/j.mayocpiqo.2021.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocpiqo.2021.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC8240169</ArticleId>
            <ArticleId IdType="pubmed">34195558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umeda Y., Hayashi H., Sugiyama S., Aoyama Y. Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis. J Dermatol. 2020;47:1322–1325. doi: 10.1111/1346-8138.15541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.15541</ArticleId>
            <ArticleId IdType="pubmed">32794214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denileukin diftitox. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases;2012-. December 27, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Plunkett W., Huang P., Searcy C.E., Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996;23(suppl 10):3–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Lau P.C., Zheng S.F., Ng W.T., Yu S.C. Inoperable pancreatic adenocarcinoma rendered complete remission by high intensity focused ultrasound concurrent with gemcitabine/capecitabine chemotherapy: case report and topic review. J Dig Dis. 2012;13:60–64. doi: 10.1111/j.1751-2980.2011.00546.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1751-2980.2011.00546.x</ArticleId>
            <ArticleId IdType="pubmed">22188918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis N., Bell D.R., Millward M.J., Levi J.A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286–291. doi: 10.1002/(sici)1097-0142(19970715)80:2&lt;286::aid-cncr17&gt;3.0.co;2-q.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0142(19970715)80:2&lt;286::aid-cncr17&gt;3.0.co;2-q</ArticleId>
            <ArticleId IdType="pubmed">9217042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlesi F., Villani P., Doddoli C., et al.  Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18:85–91. doi: 10.1046/j.0767-3981.2003.00206.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.0767-3981.2003.00206.x</ArticleId>
            <ArticleId IdType="pubmed">14748759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta N., Ahmed I., Steinberg H., et al.  Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002;25:96–100. doi: 10.1097/00000421-200202000-00021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000421-200202000-00021</ArticleId>
            <ArticleId IdType="pubmed">11823707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Els N.J., Miller V. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest. 1998;114:1779–1781. doi: 10.1378/chest.114.6.1779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.114.6.1779</ArticleId>
            <ArticleId IdType="pubmed">9872221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahan L., Ressiot E., Cournede A., et al.  Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer. Gastroenterol Clin Biol. 2007;31:1143–1145. doi: 10.1016/s0399-8320(07)78353-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0399-8320(07)78353-7</ArticleId>
            <ArticleId IdType="pubmed">18176375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S.H., Li D.L., Yang F., et al.  Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation. Biochimie. 2017;103:71–79. doi: 10.1016/j.biochi.2014.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2014.04.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maroz N., Weiner I.D. Secondary capillary leak syndrome related to pemetrexed exposure. Am J Kidney Dis. 2012;59:582–583. doi: 10.1053/j.ajkd.2011.12.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2011.12.031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson B.J., Peterson L.L. Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. J Oncol Pharm Pract. 2016;22:725–728. doi: 10.1177/1078155215591388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155215591388</ArticleId>
            <ArticleId IdType="pubmed">26071595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanduri S.R., Cheungpasitporn W., Thongprayoon C., et al.  Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. Kidney Int Rep. 2021;6:1416–1422. doi: 10.1016/j.ekir.2021.02.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ekir.2021.02.013</ArticleId>
            <ArticleId IdType="pmc">PMC8116758</ArticleId>
            <ArticleId IdType="pubmed">34013119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutgarts V., Jain T., Zheng J., et al.  Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020;26:1071–1076. doi: 10.1016/j.bbmt.2020.02.01.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2020.02.01</ArticleId>
            <ArticleId IdType="pmc">PMC8375362</ArticleId>
            <ArticleId IdType="pubmed">32088364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S., Seethapathy H., Strohbehn I.A., et al.  Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020;76:63–71. doi: 10.1053/j.ajkd.2019.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2019.10.011</ArticleId>
            <ArticleId IdType="pmc">PMC7311244</ArticleId>
            <ArticleId IdType="pubmed">31973908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M.D., Strohbehn I.A., Seethapathy H.S., et al.  Acute kidney injury after the CAR-T therapy tisagenlecleucel. Am J Kidney Dis. 2021;77:990–992. doi: 10.1053/j.ajkd.2020.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2020.08.017</ArticleId>
            <ArticleId IdType="pmc">PMC8060348</ArticleId>
            <ArticleId IdType="pubmed">33098925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caimi P.F., Pacheco Sanchez G., Sharma A., et al.  Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front Immunol. 2021;12:745320. doi: 10.3389/fimmu.2021.745320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.745320</ArticleId>
            <ArticleId IdType="pmc">PMC8546323</ArticleId>
            <ArticleId IdType="pubmed">34712233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesterhuis W.J., Rennings A.J., Leenders W.P., et al.  Vascular endothelial growth factor in systemic capillary leak syndrome. Am J Med. 2009;122:e5–e7. doi: 10.1016/j.amjmed.2009.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2009.01.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinoshita Y., Kasaoka S., Fujita M., et al.  Synchronized changes in serum vascular endothelial growth factor during the clinical course of chronic systemic capillary leak syndrome. Intern Med. 2010;49:791–794. doi: 10.2169/internalmedicine.49.2929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.49.2929</ArticleId>
            <ArticleId IdType="pubmed">20424373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie Z., Chan E., Yin Y., et al.  Inflammatory markers of the systemic capillary leak syndrome (Clarkson disease) J Clin Cell Immunol. 2014;5:1000213. doi: 10.4172/2155-9899.1000213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2155-9899.1000213</ArticleId>
            <ArticleId IdType="pmc">PMC4232957</ArticleId>
            <ArticleId IdType="pubmed">25405070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarychanski R., Abou-Setta A.M., Turgeon A.F., et al.  Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis [published correction appears in JAMA. 2013;309:1229] JAMA. 2013;20:678–688. doi: 10.1001/jama.2013.430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2013.430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mutchler S.M., Kleyman T.R. New insights regarding epithelial Na+ channel regulation and its role in the kidney, immune system and vasculature. Curr Opin Nephrol Hypertens. 2019;28:113–119. doi: 10.1097/MNH.0000000000000479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MNH.0000000000000479</ArticleId>
            <ArticleId IdType="pmc">PMC6349474</ArticleId>
            <ArticleId IdType="pubmed">30585851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pineton de Chambrun M., Luyt C.E., Beloncle F., et al. EurêClark Study Group  The clinical picture of severe systemic capillary leak syndrome episodes requiring ICU admission. Crit Care Med. 2017;45:1216–1223. doi: 10.1097/CCM.0000000000002496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCM.0000000000002496</ArticleId>
            <ArticleId IdType="pubmed">28622216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert M., Launay D., Hachulla E., et al.  High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Crit Care Med. 2008;36:2184–2187. doi: 10.1097/CCM.0b013e31817d7c71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCM.0b013e31817d7c71</ArticleId>
            <ArticleId IdType="pubmed">18552679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibata S., Sato T., Takada K., et al.  Isoform D of vascular endothelial growth factor in systemic capillary leak syndrome: a case report. J Med Case Rep. 2016;10:125. doi: 10.1186/s13256-016-0894-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13256-016-0894-7</ArticleId>
            <ArticleId IdType="pmc">PMC4937526</ArticleId>
            <ArticleId IdType="pubmed">27386947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yabe H., Yabe M., Koike T., et al.  Rapid improvement of life-threatening capillary leak syndrome after stem cell transplantation by bevacizumab. Blood. 2010;115:2723–2724. doi: 10.1182/blood-2009-11-247056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-11-247056</ArticleId>
            <ArticleId IdType="pubmed">20360479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowden A.M., Rullo O.J., Aziz N., et al.  Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks. J Allergy Clin Immunol. 2009;124:1111–1113. doi: 10.1016/j.jaci.2009.06.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.06.043</ArticleId>
            <ArticleId IdType="pubmed">19703708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gousseff M., Arnaud L., Lambert M., et al.  The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med. 2011;154:464–471. doi: 10.7326/0003-4819-154-7-201104050-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-154-7-201104050-00004</ArticleId>
            <ArticleId IdType="pubmed">21464348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacal P.M., Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018;136:97–107. doi: 10.1016/j.phrs.2018.08.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2018.08.023</ArticleId>
            <ArticleId IdType="pubmed">30170190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonifant C.L., Jackson H.J., Brentjens R.J., Curran K.J. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi: 10.1038/mto.2016.11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/mto.2016.11</ArticleId>
            <ArticleId IdType="pmc">PMC5008265</ArticleId>
            <ArticleId IdType="pubmed">27626062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neelapu S.S., Tummala S., Kebriaei P., et al.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62. doi: 10.1038/nrclinonc.2017.148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.148</ArticleId>
            <ArticleId IdType="pmc">PMC6733403</ArticleId>
            <ArticleId IdType="pubmed">28925994</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
